Loyola University Chicago

Loyola eCommons
Master's Theses

Theses and Dissertations

2021

Characterization of Alcohol-Mediated Promotion of Breast Cancer
Stem Cells
Mckenna Below

Follow this and additional works at: https://ecommons.luc.edu/luc_theses
Part of the Cell Biology Commons

Recommended Citation
Below, Mckenna, "Characterization of Alcohol-Mediated Promotion of Breast Cancer Stem Cells" (2021).
Master's Theses. 4379.
https://ecommons.luc.edu/luc_theses/4379

This Thesis is brought to you for free and open access by the Theses and Dissertations at Loyola eCommons. It
has been accepted for inclusion in Master's Theses by an authorized administrator of Loyola eCommons. For more
information, please contact ecommons@luc.edu.
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.
Copyright © 2021 Mckenna Below

LOYOLA UNIVERSITY OF CHICAGO

CHARACTERIZATION OF ALCOHOL-MEDIATED PROMOTION OF
BREAST CANCER STEM CELLS

A THESIS SUBMITTED TO
THE FACULTY OF THE GRADUATE SCHOOL
IN CANDIDACY FOR THE DEGREE OF
MASTER OF SCIENCE

PROGRAM IN INTEGRATIVE CELL BIOLOGY

BY
MCKENNA N. BELOW
CHICAGO, IL
DECEMBER 2021

TABLE OF CONTENTS
LIST OF FIGURES

iv

LIST OF TABLES

vi

ABSTRACT

vii

CHAPTER ONE: INTRODUCTION
Cancer and Modifiable Risk Factors
Breast Cancer: General Overview
Overview of the Estrogen Receptor Signaling Pathway
Overview of the Notch Signaling Pathway
Notch Signaling and Breast Cancer
Cancer Stem Cell Hypothesis
Maintenance of Breast Cancer Stem Cells by Notch Signaling
Maintenance of Breast Cancer Stem Cells by Estrogen Signaling
Alcohol and the Promotion of Stemness

1
1
2
4
6
9
10
11
12
14

CHAPTER TWO: PRELIMINARY DATA, HYPOTEHSIS, AND SPECIFIC AIMS
16
Preliminary Data
16
Central Hypothesis
18
Specific Aims
18
Aim 1: Elucidate potential mechanisms by which alcohol promotes breast cancer stem cells
in naïve ER+ breast cancer cells.
18
Aim 1a
18
Aim 1b
18
Aim 2: Determine the effect of alcohol in long-term estrogen deprived (LTED) ER+ breast
cancer stem cells.
19
Aim 2
19
CHAPTER THREE: MATERIALS AND METHODS
Materials
Cell Culture
Drug Treatments
Antibodies
Primers
Experimental Methods
Western Blotting
Bicinchoninic Acid (BCA) Assay
Gel preparation
Western blot
Reverse Transcription, Real Time Polymerase Chain Reaction (PCR)
RNA extraction
Reverse Transcription (RT)
Quantitative Real Time PCR

ii

21
21
21
21
22
23
23
23
23
24
25
26
26
26
27

Mammosphere Formation Assay

28

CHAPTER FOUR: RESULTS
30
Specific Aim 1: Elucidate Potential Mechanisms by Which Alcohol Promotes Breast Cancer
Stem Cells in Naïve ER+ Breast Cancer Cells.
30
Acute Alcohol Exposure Induces Expression of CSC-Promoting Genes
30
Alcohol Attenuates Transcriptional Regulation of ER Targets by 17-estradiol
33
Alcohol Promotes Expression of Notch4 in a Dose-Dependent Manner
35
The Effect of -Secretase Inhibition in Bulk and/or BCSCs on BCSC Survival
37
Alcohol May Promote the Interaction of the -Secretase Complex with Notch4.
38
BCSCs are Resistant to GSI Treatment in Bulk Cells Prior to Selection
40
Alcohol Promotes Resistance in GSI-Treated BCSCs
41
Specific Aim 2: Determine the Effect of Alcohol on Long-Term Estrogen Deprived ER+
Breast Cancer Stem Cells
43
CHAPTER FIVE: DISCUSSION

47

REFERENCE LIST

55

VITA

73

iii

LIST OF FIGURES
Figure 1. Molecular Mechanisms of Estrogen Receptor Signaling to Regulate Gene Expression
& Physiological Responses.
4
Figure 2. Structure of the Notch Ligands Receptors.

8

Figure 3. Canonical Notch Signaling Mechanisms to Mediate Transcriptional Activation of
Downstream Targets & Pharmacological Inhibitors.

8

Figure 4. The role of ER in Normal Tissue and Breast Cancer Stem Cell Maintenance.

13

Figure 5. Alcohol Metabolism Results in the Production of Acetylaldehyde and Increased
ROS Formation.

15

Figure 6. Alcohol Enhances BCSC Survival in a Dose-Dependent Manner in Naïve ER+ Cells,
Regardless of 17-estradiol.
17
Figure 7. Alcohol Dose-Dependently Enhances BCSC Size in Naïve ER+ Cells.

17

Figure 8. Expression of HES1 RNA Trends Upwards in Response to Alcohol.

31

Figure 9. Alcohol Treatment Trends Toward Inducing Expression of Pluripotent Genes.

33

Figure 10. Alcohol Alone Induced Expression of Classical ER Target Genes.

34

Figure 11. Alcohol Dose-Dependently Enhances Notch4 Protein Expression.

36

Figure 12. Alcohol Dose-Dependently Enhances DAXX Protein Expression in the Presence of
17-estradiol.
37
Figure 13. Experimental Design of -Secretase Complex Inhibition in Bulk Cells and/or
BCSCs.

38

Figure 14. Confirmation of -Secretase Complex Inhibition by Target Protein Expression
Analysis

39

Figure 15. Accumulation of Notch4 Following -Secretase Inhibition is Enhanced by
Exposure to Alcohol

40

iv

Figure 16. GSI Treatment in Bulk Cell Populations Results in Resistant BCSC Populations.

43

Figure 17. Alcohol Exposure Trends Towards Enhanced BCSCs Survival in
17-estradiol treated LTED ER+ Cells

45

Figure 18. Alcohol Enhances Notch4 and DAXX protein expression in LTED ER+ cells.

46

Figure 19 Regulation of Notch Signaling by 17-estradiol mediated Activation of the Estrogen
Receptor.
48
Figure 20. Alcohol Regulation of 17-estradiol Mediated ER Activity

v

50

LIST OF TABLES
Table 1. Real-time RT-PCR Primers

22

Table 2. Gel Preparation for Western Blot

24

Table 3. Reverse Transcription Reaction (50L)

27

Table 4. Real-time RT-PCR Reaction (12.5L)

28

vi

ABSTRACT
Breast cancer is the leading cause of cancer-related death in women globally, and one in
eight women will be diagnosed with breast cancer at some point in her life. Alcohol consumption
has been linked to increase breast cancer risk and increased risk of tumor recurrence.
Understanding the molecular mechanisms of modifiable lifestyle factors such as alcohol
consumption will help to lower these risks and design more effective therapeutic approaches.
Estrogen Receptor positive (ER+) breast cancer comprises approximately 70% of all breast
cancers, and these tumors are effectively targeted by endocrine therapy in the form of estrogen
deprivation with aromatase inhibitors, a selective estrogen receptor modifier (tamoxifen), or a
selective estrogen receptor degrader (fulvestrant). However, resistance to endocrine therapy
poses a major threat to women with ER+ breast cancer. One proposed mechanism for drug
resistance and tumor recurrence is explained by the cancer stem cell hypothesis, which states that
tumors are composed of a heterogenous cell population that consists of differentiated and stemlike cells, coined cancer stem cells (CSCs). CSCs are able to evade endocrine therapy and remain
dormant until later reactivated by the microenvironment, in which they then re-bulk a tumor,
usually at the metastatic site. The effects of alcohol on ER+ breast CSCs have yet to be
elucidated. The CSC population is known to be maintained by a variety of signaling pathways.
Estrogen signaling is thought to maintain a differentiated state and suppress pluripotent
populations, whereas Notch signaling is a known promoter of CSC populations and a necessary
component of their survival. Thus, we propose the central hypothesis that alcohol promotes ER+
breast cancer stem cells through the activation of Notch signaling.

vii

Preliminary data show that alcohol enhances ER+ breast CSC survival regardless of the
presence of estrogen. Results show that Notch target genes HES1, SOX2, and others are induced
upon exposure to 40mM ethanol in naïve ER+ breast cancer cells. On the contrary, exposure to
ethanol resulted in attenuated induction of classic ER targets PS2 and PGR in response to
treatment with 5nM estradiol. Additionally, inhibition of Notch signaling by a -secretase
inhibitor had no effect on the ability of ethanol to enhance breast CSC survival when estrogen
was present, however under estrogen deprivation conditions Notch inhibition prevented breast
CSC survival in the presence of ethanol. Lastly, investigation into the effects of alcohol on an
endocrine therapy resistant cell line show a positive trend in breast CSC survival and induced
Notch activation.
Taken together, these results indicate that alcohol mediates breast CSC survival partly
through Notch activity under estrogen deprived conditions. However, Notch signaling may not
be necessary for alcohol’s effect on the CSC population when estrogen is present based on our
findings using a GSI in breast CSCs. Further studies are necessary to investigate the exact
mechanism of alcohol on estrogen signaling and determine if the Notch activation seen when
alcohol is present is due to direct activation of the pathway or through inhibition of its negative
regulator, ER.
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CHAPTER ONE
INTRODUCTION
Cancer and Modifiable Risk Factors
Cancer is a significant global burden, with 19.3 million new cases diagnosed and 10
million cancer-related deaths worldwide in the year 2020 (Sung et al., 2021). It is well known
that cancer risk is positively impacted by a variety of modifiable lifestyle factors such as physical
activity, tobacco use, and diet (Stein & Colditz, 2004, Islami et al., 2018, Gapstur et al., 2018).
Among these modifiable factors is alcohol – a classified Group 1 carcinogen as of the year 1988
(Scheilder & Klein, 2018, Testino, 2011). In the year 2019, 69.5% of people aged 18 years or
older reported having drank alcohol within the last year, and 54.9% having drank within the last
month (SAMHSA Table 2.18B, SAMHSA Table 2.19B). Alcohol is known to increase the risk
of at least seven different types of cancer: bowel, oral, pharynx, oesophagus, colon, rectum, and
female breast cancer (Connor, 2016, Lopez-Lazaro, 2016, Boffetta and Hashib, 2006, Testino,
2011, Scheilder & Klein, 2018). In young adults, ages 30-34, breast cancers accounted for 18.4%
of all alcohol-attributable cancer deaths (Rehm et al., 2020). For every 10 grams of alcohol
consumed per day, the risk of breast cancer development increases by 10% in adult women,
regardless of menopausal status (Liu et al., 2015) and a 40-50% increase in breast cancer risk
seen in women consuming more than three alcoholic beverages a day (Seitz et al., 2021).
Drinking 6 grams or more per day also correlates with increased risk of breast tumor recurrence
and death, and this risk appears to be elevated in post-menopausal women (Kwan et al., 2010,
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Kwan et al., 2013, Simapivapan et al., 2016), however the molecular mechanisms by which
alcohol promotes this increased risk have yet to be elucidated.
Early in vitro studies suggest that alcohol promotes proliferation of Estrogen Receptor
positive (ER+) breast cancer cell lines through the stimulation of estrogen signaling. Cells treated
with increasing concentrations of ethanol showed increased proliferation, increased expression of
both ER and aromatase, the enzyme responsible for estrogen synthesis, and intracellular cAMP
levels (Fan et al., 2000, Singletary et al., 2001). More recent studies suggest that alcohol
regulates transcription of RNA Polymerase III genes in an ER dependent manner (Zhang et al.,
2012), and microarray datasets have shown that alcohol consumption correlated with
upregulation of genes associated with recurrence, metastasis, and death in ER+ tumor samples
being managed by endocrine therapy (Candelaria et al., 2015).
Breast Cancer: General Overview
In the year 2020, female breast cancer became the most commonly occurring cancer
globally, overtaking lung cancer (Sung et al, 2021, Siegel et al., 2021). A projected 43,600
women will lose their life to breast cancer in the year 2021 according to recent studies (Siegel et
al., 2021). Breast cancer can originate from any of the major tissues found within the breast,
resulting in either invasive ductal carcinoma, which comprise approximately 80% of all breast
cancer diagnoses, or invasive lobular carcinoma which account for about 10% of breast cancers
(Wasif et al., 2010, Barroso-Saousa and Metzger-Filho 2016).
There are known genetic mutations that are associated with increased breast cancer risk,
such as mutations in the BRCA1 and BRCA2 genes (Maric et al., 2011, Rosen et al., 2003), as
well as TP53, PTEN, ATM, and others (Sheikh et al., 2015, Greenblatt et al., 2001, Broeks et al.,
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2000). However, the mechanism by which alcohol contributes to the mutation of these genes or
the interplay of these mutations with alcohol consumption to promote breast cancer remain under
studied (Freudenheim et al., 2004, Dennis et al., 2010, Scoccianti et al., 2014).
Breast cancer is a heterogeneous disease that is classified by its diverse molecular
subtypes as defined by protein expression of the Estrogen Receptor (ER), Progesterone
Receptor (PR), and/or the Human Epidermal Growth Factor Receptor 2 (HER2) (Dai et al.,
2016). These tumors can then be further classified as luminal tumors, which express ER with or
without expressing PR, or basal-like tumors which lack expression of ER, PR, or HER2 and are
generally defined by expression of cytokeratins 5, 14, and 17 (Sims et al. 2007).
Tumors that are classified as ER+ and/or PR+ can be effectively targeted using
endocrine therapy, which includes the use of tamoxifen, a selective estrogen receptor modifier
(SERM), letrozole, anastrozole, or exemestane, an aromatase inhibitor (AI), and/or fulvestrant, a
selective estrogen receptor degrader (SERD). Aromatase inhibitors have been shown to
significantly improve disease-free survival (DFS) after five years of treatment for postmenopausal women (Hussain et al., 2004, Tremont et al., 2017). Tamoxifen is approved for premenopausal women and has been shown to significantly increase overall survival after five years
of adjuvant therapy (Boccardo et al., 1998, Higgens et al., 2013, Colleoni & Munzone, 2015).
Tumors classified as HER2+ overexpress the receptor tyrosine kinase due to a gene amplification
of the proto-oncogene ERBB2. HER2+ targeted therapies include humanized monoclonal
antibodies, such as trastuzumab and pertuzumab (Gianni et al., 2016, Howie et al., 2019, Hudis
2007), or second-line therapies such as lapatinib or neratinib, which inhibits tyrosine kinase
activity (Jones et al., 2009). Tumors that lack expression or overexpression of ER, PR, and/or
HER2 are classified as triple negative, and these tumors lack approved targeted therapies and
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thus are treated with cytotoxic mitotic disruptors (i.e. paclitaxel) or genotoxic (i.e. carboplatin)
chemotherapy (Hatzis et al., 2015, Ishikawa et al., 2011, Pal et al., 2011, Sharma et al., 2018).
Overview of the Estrogen Receptor Signaling Pathway
The Estrogen Receptor was first discovered in 1958 (Jensen et al., 1967, Jensen et al.,
1968), and was later cloned using an ER+ breast cancer cell line, MCF-7 (Green et al., 1986).
Shortly after its discovery, the role for ER in breast cancer as a prognostic marker was
established (Knight III et al., 1977, Samaan et al., 1981, Pike et al., 1993). The predominant
endogenous ligand of ER is 17-estradiol, which is primarily produced in the ovaries and
considered the most biologically active hormone in human breast tissue (Russo & Russo, 2006,
Russo et al., 2006). There are two known isoforms of the ER, ER and ER, which are both a
part of the nuclear receptor superfamily of transcription factors (Hua et al. 2018).
The ER is
capable of signaling
through a variety of
mechanisms, which
have been summarized
in Figure 1 (McDevitt
et al., 2008). Upon
binding of its ligand,
the ER undergoes a
confirmational change that releases it from the sequestration of heat shock proteins and induces
either homo- or
heterodimerization with

Figure 1: Molecular Mechanisms of Estrogen Receptor Signaling to
Regulate Gene Expression & Physiological Responses.
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other ERs (Cowley et al., 1997, Jisa & Jungbauer 2003). Its classical signaling mechanism is
through direct binding of DNA at the Estrogen Response Element (ERE) upon translocation
from the cytosol to the nucleus (Hall et al., 2001). Upon binding to the ERE, ER directs
transcription of its downstream targets through the recruitment of co-factors, such as the coactivators that include steroid receptor coactivators (SRC-1, -2, or -3), p300CBP, and histone
acetyl transferases (HATs) or co-repressors such as NcoR or SMRT and histone deacetylases
(HDACs) (Sommer & Fuqua, 2001). Alternatively, the ER can regulate transcription without
needing to directly bind to the ERE. It does so mainly through protein-protein interactions, such
as binding directly to AP-1 or Sp-1 via its AF-1 and AF-2 domains (Yasar et al. 2016, Fuentes &
Silveyra, 2019). There also exists a non-nuclear ER known as GPER-1, which is a G-protein
coupled receptor (GPCR) whose endogenous ligand is also E2 and is known to increase
intracellular calcium levels and cAMP production upon activation (Ranganathan et al., 2019).
Lastly, ER signaling can be activated independent of its ligand by other intracellular signaling
pathways. For example, it is well known that MAPKs such as ERK1/2 can phosphorylate ER at
Serine 118 to activate the receptor in response to Epidermal Growth Factor (EGF) stimulation
(Coleman & Smith, 2001, Bunone et al., 1996).
As stated previously, expression of the ER defines the molecular subtype of breast cancer
tumors, with ER+ tumors comprising approximately 70% of all breast cancer cases (Rosenberg
et al., 2015, Ferreira Almeida et al., 2020). Normally, ER expressing luminal cells in the breast
rarely proliferate (Band & Laiho, 2011), yet activation of ER by E2 is known to stimulate cell
growth and proliferation in ER+ breast cancer cells (Chalbos et al., 1982, Mense et al., 2008). ER
status in breast tumors is associated with differences in gene expression patterns (Lu et al., 2008,
Gruvberger et al., 2001), specifically ER+ tumors show significantly upregulated genes involved
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in cell growth (CCND1, CMYC) DNA binding, and transcription factor activity (Abba et al.,
2005).
Overview of the Notch Signaling Pathway (Originally published in BeLow & Osipo, 2020)
Notch signaling is an evolutionary conserved pathway, originally discovered through
investigations of Drosophila wing development (Artavanis-Tsakonas et al., 1995) and has since
grown into an increasingly large field of study for cancer biologists. This intricate pathway
mediates normal stem cell differentiation, cell fate, and organ development (Lai, 2004, Chiba,
2006). However, its dysregulation and role in promoting cellular transformation has led to
further investigations of the role of Notch in a variety of cancers (Miele et al., 2013).
There exist four known mammalian Notch receptors, Notch1, Notch2, Notch3, and
Notch4. Each receptor is translated as a single polypeptide that is subsequently cleaved in the
Golgi-apparatus by a furin-like convertase. The resulting cleaved protein is delivered to the
plasma membrane as a heterodimeric protein containing an extracellular domain tethered to the
transmembrane and intracellular domains by a calcium cation, as shown in Figure 2 (BeLow &
Osipo, 2020). Upon interaction of the extracellular domain with one of its ligands that include
Jagged-1 (JAG1), Jagged-2 (JAG2), Delta-like 1 (DLL1), Delta-like 3 (DLL3), or Delta-like 4
(DLL4), through cell-to-cell contact (Figures 1 and 2), the extracellular portion of the receptor is
pulled away from the transmembrane/intracellular domains by ligand-mediated endocytosis. The
remaining transmembrane portion of the receptor (NotchTM) is first cleaved by a disintegrin and
metalloprotease (ADAM17 or ADAM10), resulting in a product: Notch extracellular truncation
(NEXT). NEXT is subsequently cleaved by the γ-secretase complex releasing the intracellular
portion of Notch (NotchIC). NotchIC is translocated from the cytoplasm to the nucleus where it
binds to the CSL (CBF-1/RBPJ-κ in Homo sapiens/Mus musculus, respectively, Suppressor of
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Hairless in Drosophila melanogaster, Lag-1 in Caenorhabditis elegans) transcription factor. The
interaction of NotchIC with CSL replaces corepressors with coactivators including the
transcriptional activator Mastermind1 (MAML1) at regulatory sequences of gene targets (Figure
3, BeLow & Osipo, 2020). This allows for transcriptional activation of Notch target genes
(Andersson et al., 2011, Kopan et al., 2009).
Some of the earliest known targets of Notch signaling include transcriptional repressors,
such as the hairy/enhancer of split (HES) genes, as well as the HES subfamily members HEY1,
HEY2, and HEYL (Borggrefe et al., 2009, Fischer et al., 2004). These HES/HEY genes are critical
cell-fate regulators during development and tissue renewal. In addition to this, cell-cycle
regulators such as c-Myc (Klinakis et al., 2006) and cyclin D1 (Cohen et al., 2009) are directly
activated by Notch signaling. Dysregulation of Notch signaling, such as activating Notch
receptor mutations, overexpression of ligands and/or receptors, and/or overexpression of its
target genes, contributes to increased proliferation, cell transformation, and increased drug
resistance in cancers of the breast, multiple myeloma, prostate, T-cell acute lymphoblastic
leukemia, and others (Bolós et al., 2007).
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Figure 2: Structure of the Notch Ligands and Receptors.

Figure 3: Canonical Notch Signaling Mechanisms to Mediate Transcriptional Activation of
Downstream Targets & Pharmacological Inhibitors.
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Notch Signaling and Breast Cancer (Originally published in BeLow & Osipo, 2020)
It has been shown that Notch is an oncogene in the breast, as overexpression of Notch1 IC
(Dievart et al., 1999, Hu et al., 2006), Notch3IC (Hu et a., 2006), or Notch4IC (Jhappan et al.,
1992, Rafaat et al., 2004) is sufficient for transformation of normal breast epithelial cells into
cancer cells. Overexpression of Notch1 and/or Jagged1 predicts the poorest overall survival
outcome for women with breast cancer (Dickson et al., 2007, Reedijk et al.,2005). Early studies
show that normal breast tissue has high expression of the negative Notch regulator, Numb, and
that its expression is lost in breast tumors (Pece et al., 2004). Treatment with the proteasome
inhibitor MG-132 led to increased Numb expression in primary cultures of human breast tumor
cells and decreased Notch transcriptional activity. Based on these findings, Stylianou and
colleagues investigated whether Notch was aberrantly activated in breast cancer and how this
may impact cellular transformation. Upon stable overexpression of Notch1IC in the nontransformed breast cell line MCF-10A, they were able to demonstrate cellular transformation via
changes in cell shape, increased cell growth, colony formation, and resistance to apoptosis.
Importantly, overexpression of Numb in the ER+ breast cancer cell line MCF-7 resulted in
decreased NotchIC accumulation, inhibition of colony formation, and accumulation of Ecadherin, suggesting that transformation of these cells had been reversed (Stylianou et al., 2006).
Together, these data demonstrate that increased Notch activity and/or deregulation of Notch
leads to the transformation of normal breast cells into cancer cells.
Expression and activation of Notch in primary breast tumors has been used to assess if
Notch signaling is a prognostic and/or predictive biomarker. For example, overexpression of
Notch1 and Jagged1 predict the poorest overall outcome for women with breast cancer, with a
predicted mortality of 63% in women with JAG1high-expressing tumors, compared to 32% in

JAG1low-expressing

tumors. Furthermore, women with

Notch1high-expressing
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tumors had a 66%

mortality rate, compared to 30.5% for Notch1low-expressing tumors (Reedijk et al., 2005). A
study conducted by Yao and colleagues (2011) identified that expression of Notch1 and Notch4
proteins was cytoplasmic in ER+ breast tumors, compared to ER− tumors. In conjunction with
this, Ki67 expression, a nuclear protein associated with proliferation (Yao et al., 2010),
significantly correlated with Notch1 nuclear expression and Notch4 membrane and cytoplasmic
expression in ER+ tumors. Further research demonstrated that Notch1 and Notch4
immunoreactivity significantly correlated with tumor grade and Ki67 expression in triplenegative breast tumors (Speiser et al., 2011). These findings and others (Dickson et al., 2007,
Reedijk et al., 2007, Xing et al., 2011, Speiser et al., 2013, Pandya et al., 2015, Strati et al., 2017)
provided support for Notch as a poor prognostic biomarker in breast cancer.
Cancer Stem Cell Hypothesis (Originally published in BeLow & Osipo, 2020).
One proposed theory for drug resistance and tumor recurrence is that a small population
of cells referred to as breast cancer stem-like cells (BCSCs) within the bulk primary tumor are
inherently resistant to many forms of targeted or cytotoxic therapy. These BCSCs survive
therapy and remain dormant until they are reactivated to proliferate, depending on the
microenvironment. A small population of CD44+/CD24−/low cells were originally isolated from
patient tumors in 2003 by Al-Hajj et al., in which these cells were found to have high tumorinitiating potential, 10- to 50-fold greater than CD44+/CD24+ cells, when injected into immunecompromised mice. These cells were coined “cancer stem cells” due to their high tumor
initiating potential and their ability to form distinct populations of stem-like and differentiated
cells within the bulk tumor (Al-Hajj et al., 2003).
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Alternatively, stem cells can be identified by measuring the enzymatic activity of
Aldehyde Dehydrogenase (ALDH). ALDH is expressed across normal tissue and is responsible
for the oxidation of intracellular aldehydes produced from alcohol metabolism by alcohol
dehydrogenase (Cederbaum, 2012, Vassali, 2019). However, it’s elevated activity in neural and
hematopoietic stem cells (Corti et al., 2006, Armstrong et al., 2004, Storms et al., 1999, Chute et
al., 2006), along with multiple myeloma and acute myeloid leukemia cells (Cheung et al., 2007,
Matsui, et al., 2008) led researchers to investigate its role in mammary stem cells. Ginestier and
colleagues (2007) established that high ALDH activity was found in both normal breast
epithelium along with cells collected from human-derived breast cancer xenotransplants. Using
the ALDEFLOUR assay, which utilizes a fluorescent aldehyde to detect ALDH activity (Zhou et
al., 2019), they were able to establish that ALDEFLOUR positive cells had high tumorgenicity,
and ultimately that the isoform ALDH1 was a viable diagnostic biomarker and predictor of poor
clinical outcomes (Ginestier et al., 2007, Balicki, 2007).
Maintenance of Breast Cancer Stem Cells by Notch Signaling
The mammary glands are derived from mammary stem cells that differentiate into
luminal and myoepithelial progenitors, and these further differentiate into luminal and
myoepithelial cells. Mammary stem cells were originally investigated using a unique suspension
cell culture technique (Dontu et al., 2004). Single cell suspensions were cultured in a
mammosphere-forming medium, as the term “mammosphere” is derived from the ability of the
cells to proliferate in suspension in the form of a sphere, as previously seen using neuronal stem
cells which formed “neurospheres” (Dontu et al., 2004, Reynolds & Weiss, 1996).
Dontu and colleagues were the first to use this assay to show activation of Notch
signaling promotes proliferation and self-renewal of mammary stem/progenitor cells. Further, the
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investigators demonstrated that Notch signaling was also required for the lineage commitment of
mammary progenitors to myoepithelial cells in vivo as either Notch4 blockade or a -secretase
inhibitor (GSI) inhibited the myoepithelial lineage commitment (Dontu et al., 2004). This
technique was then utilized to isolate Ductal Carcinoma in Situ (DCIS) cells from human breast
tissues, and researchers were able to demonstrate a direct role for Notch by inhibiting the
mammosphere forming ability of these cells, using the GSI DAPT (Farnie et al., 2007).
Interestingly, Notch target genes were shown to be elevated in mammospheres derived from
various breast cancer cell lines (Grudzien et al., 2010); and ALDEFLOUR+ breast cancer cells
had increased mammosphere-forming efficiency (MFE), compared to ALDEFLOUR− cells,
which correlated with an increased expression in Notch2 mRNA, a known promoter of
mammary stem cell self-renewal (Charafe-Jauffret et al., 2009).
Maintenance of Breast Cancer Stem Cells by Estrogen Signaling
It is known that estrogen plays a critical role in promoting breast epithelial cell
differentiation (Bocchinfuso et al., 2000). However, only a small percentage of cells in the
mammary gland express ER during development, and these cells were considered to be
permanently differentiated due to their lack of proliferative markers (Shoker et al., 1999). Dontu
and colleagues proposed an alternative hypothesis that ER+ cells found in the breast represent
undifferentiated stem or progenitor cells that are slowly dividing that then give rise to more
rapidly dividing cell populations that vary in ER status when stimulated by E2, as summarized in
Figure 4 (Dontu et al., 2004). More recent studies have shown that ER+ cells are exclusively
maintained by a lineage-restricted, ER+ stem cell population (Van Keymeulen et al., 2017), thus
supporting a role for estrogen signaling in the maintenance of stem cell populations in healthy
breast tissue.
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Figure 4: The Role of ER in Normal Tissue and Breast Cancer Stem Cell Maintenance.
The mammosphere formation assay that has been previously described allows for a more
in-depth study of both mammary stem cells and breast cancer stem cells. Simões and co-workers
investigated the effect of estrogen on stem cell populations in both normal mammary epithelial
cells, as well as in ER+ breast cancer cells. Their data showed that treatment with E 2
significantly reduced the expression of pluripotent genes, such as NANOG, SOX2, and OCT4 in
the differentiated cells compared to the mammosphere populations in both normal mammary
cells and breast cancer cells (Simões et al., 2011). Additionally, treatment with the SERM
Tamoxifen has been shown to significantly increase the number of mammospheres compared to
cells grown in the presence of E2 (Simões et al., 2011, Raffo et al., 2013). Interestingly, previous
studies suggest that this promotion of stemness following estrogen antagonism is mediated by
Notch4 activity and correlated with increased expression of ALDH1 (Simões et al., 2015,
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Rodriguez et al., 2019, Sarmiento-Castro et al., 2020). Studies have shown that ER+ breast
cancer cell lines treated with estrogen-deprivation therapy, Tamoxifen or fulvestrant, have
increased expression of the cleaved forms of Notch1 (Notch1IC) and Notch4 (Notch4IC) (Rizzo
et al., 2008). Specifically, endocrine-therapy-induced Notch1IC and Notch4IC increased CSLdriven reporter activity in ER+ MCF-7 and T47D cells, suggesting that, while E2-mediated
activation of ER maintained low Notch activity, antagonizing ER increased Notch signaling.
Together, these data support the further investigation of the interplay of Notch and ER signaling
in maintaining the breast cancer stem cell population.
Alcohol & the Promotion of Stemness
The role of alcohol consumption in the differentiation and maintenance of stem cells has
been extensively studied specifically in neural stem cells and embryonic stem cells as a model
for studying Fetal Alcohol Spectrum Disorders (FADS). Early studies show that exposure to
ethanol inhibits proliferation and induces apoptosis in neural stem cells through disruption of
growth factor signaling (Crews et al., 2003, Crews et al., 2003). Additional studies showed that
ethanol redistributes cell lineage through maintaining elevated expression of the pluripotent
genes OCT4, SOX2, and NANOG in both mouse and human embryonic stem cells (Arzumnayan
et al., 2009, Sánchez-Alvarez et al., 2013). The effects of alcohol exposure on mammary stem
cells have yet to be elucidated.
As mentioned previously, a hallmark for cancer stem cells is elevated expression and/or
activity of the enzyme Aldehyde Dehydrogenase, or ALDH. When ethanol enters the cell, it
undergoes oxidative metabolism by Alcohol Dehydrogenase (ADH) and cytochrome P450 2E1
(CYP2E1) to form acetylaldehyde and increase the level of reactive oxygen species (ROS).
Acetylaldehyde, a known carcinogen, is then further metabolized by ALDH into acetate which is
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then finally metabolized into CO2 and water to be eliminated, as reviewed in Figure 5 (Di Rocco
et al., 2019). It has been suggested that alcohol contributes to tumorigenesis potentially through
the production of ROS to maintain the cancer stem cell pool (Di Rocco et al., 2019, Xu & Luo,
2017). More specifically, a study using HER2 overexpressing breast cancer cells showed that
alcohol exposure increased the cancer stem cell population through activation of the p38/MAPK
pathway (Xu et al., 2016), thus providing strong rationale to examine the effects of alcohol on
ER+ breast cancer stem cells.

Figure 5: Alcohol Metabolism Results in the Production of Acetylaldehyde and Increased
ROS Formation.

CHAPTER TWO
PRELIMINARY DATA, HYPOTHESIS, AND SPECIFIC AIMS
Preliminary Data
Previous studies have focused on the role of HER2 signaling and utilized HER2+ breast
cancer cell lines to investigate alcohol’s effect on BCSCs (Xu et al., 2016), however little is
known about the response of naïve ER+ breast cancer cells to alcohol exposure. We sought to
determine whether treatment with increasing concentrations of ethanol would result in changes in
the CSC population of the ER+ breast cancer cell line MCF-7. Cells were grown in the presence
of 5nM 17-Estradiol or a DMSO vehicle control in phenol red-free RPMI media while
simultaneously being treated with 0, 10, 20, or 40mM ethanol for 72 hours. Cells were then
individualized, counted, and seeded at a density of 2.5 x 104 cells into mammosphere forming
medium, and incubated at 37°C for 7 days. After the incubation period was over, cells were
imaged prior to extraction, and mammosphere forming efficiency was calculated. In addition to
this, we assessed the differences in mammosphere size using ImageJ software analysis. Our
findings show that exposure to alcohol enhances mammosphere forming efficiency, with a
significant change shown at 20mM ethanol compared to 0mM controls (Figure 6). Interestingly,
there was a dose-dependent increase in mammosphere size in response to alcohol in both the
presence and absence of 17-Estradiol (Figure 7).
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Figure 6: Alcohol Enhances BCSC Survival in a Dose-Dependent Manner in Naïve ER+
Cells, Regardless of 17-Estradiol. MCF-7 cells were grown in charcoal-stripped phenol-red
free RPMI for 72 hours. Then they were treated with 5nM 17-Estradiol or DMSO alone or in
combination with increasing concentrations of ethanol. 2.5 x 104 cells were seeded into
mammosphere media and incubated for 7 days, after which %MFE was calculated. Results are
presented as the mean + SD of three independent experiments. Two-Way ANOVA with Tukey’s
multiple comparisons analysis was used to determine statistical significance. (** = p<0.01).
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Figure 7: Alcohol Dose-Dependently Enhances BCSC Size in Naïve ER+ Cells. MCF-7 cells
were treated as previously described in Figure 6. Cells were imaged at 20X magnification and
size analysis was performed using ImageJ software. Results are presented as the mean + SD of
three independent experiments. Two-Way ANOVA with Tukey’s multiple comparisons analysis
was used to determine statistical significance. (* = p<0.05, ** = p < 0.01).
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Central Hypothesis
Based on previous findings and preliminary data, we propose the following hypothesis:
alcohol promotes cancer stem cell survival in estrogen receptor positive breast cancers
through the stimulation of Notch signaling. The following specific aims have been designed to
test potential mechanisms by which alcohol promotes breast cancer stem cells, and how this may
change in the context of long-term estrogen deprivation in vitro.
Specific Aims
Aim 1: Elucidate Potential Mechanisms by Which Alcohol Promotes Breast Cancer Stem
Cells in Naïve ER+ Breast Cancer Cells.
Aim 1A: To test whether alcohol promotes breast CSC survival through enhancement of
the Notch signaling pathway, we utilized RT-PCR to assess changes in expression of the Notch
canonical target gene HES1, as well as NOTCH1 following 72 hours of ethanol exposure in
conjunction with 5nM E2. Additionally, we assessed changes in pluripotent gene expression,
specifically of SOX2, OCT4, and NANOG as it is known that Notch signaling can regulate the
expression of these genes in order to promote CSC survival. Lastly, we tested the hypothesis that
Notch signaling is responsible for alcohol-mediated promotion of breast CSCs by attenuating
Notch signaling in conjunction with alcohol treatment in the bulk cell population prior to
incubation in mammosphere forming media. If alcohol is dependent on Notch signaling for the
promotion of breast CSCs, then we would expect that treatment with a GSI would inhibit the
enhanced MFE shown in our preliminary experiments following exposure to alcohol in MCF-7
cells.

19
Aim 1B: In order to determine if alcohol promotes breast CSC survival and growth
through inhibition of estrogen signaling, we utilized real time PCR to assess changes in Estrogen
Receptor gene targets PS2 and PGR following 72 hours of ethanol treatment, and either 0-, 3-, or
24-hours exposure to 5nM E2. We also assessed changes in the protein expression of DAXX via
western blot, as it is known that inhibition of estrogen signaling results in decreased DAXX
expression resulting in increased Notch signaling. In addition to this, low levels of DAXX are
correlated with increased mammosphere forming efficiency in MCF-7 cells (Peiffer et al., 2019).
Thus, if alcohol mediates breast CSC survival through inhibition of the estrogen signaling
pathway, then we would expect to see diminished levels of ER target transcripts and decreased
protein expression of DAXX.
Aim 2: Determine the Effect of Alcohol in Long-Term Estrogen Deprived (LTED) ER+
Breast Cancer Stem Cells.
Clinical studies have suggested a strong positive correlation between alcohol
consumption and increased risk for breast cancer recurrence, specifically in post-menopausal
women (Hu et al., 2006, Liu et al., 2015). Thus, it is imperative that a more relevant model be
used to assess the effects of alcohol in ER+ breast cancer cell lines. There are currently no
published findings of alcohol exposure in an in vitro model of long-term estrogen deprivation in
breast cancer cell lines. Long-term estrogen deprived cells have acquired resistance to endocrine
therapies and no longer require E2 to stimulate their growth, thus providing a critically needed
model to better investigate the molecular mechanisms behind alcohol-mediated promotion of
breast CSCs.
Aim 2: We assessed the effects of alcohol exposure on mammosphere formation
efficiency in the long-term estrogen deprived cell line MCF-7/5C, derived from the parental
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naïve cell line MCF-7. These cells were treated with increasing concentrations of ethanol (0, 10,
20, and 40mM) for 72 hours in the presence or absence of 5nM E2, then seeded at 2.5 x 104 cells
in mammosphere forming media and left to incubate for 7 days. Mammosphere forming
efficiency and size analysis was performed to test whether acquired resistance to estrogen
deprivation results in enhanced susceptibility to alcohol-mediated CSC survival. Additionally,
we assessed changes in DAXX protein expression as well as Notch4 to determine changes in
Notch signaling following ethanol exposure.

CHAPTER THREE
MATERIALS AND METHODS
Materials
Cell Culture
MCF-7 Breast Cancer cells were purchased and obtained from American Type Culture
Collection (ATCC). A long-term estrogen deprived (LTED) variant MCF-7/5C were provided by
Dr. V. Craig Jordan (University of Texas, M.D. Anderson Center, Houston, TX). MCF-7 cells
were cultured in Roswell Park Memorial Institute Medium (RPMI 1640; Corning CellGro)
enhanced with 10% Fetal Bovine Serum (FBS, Corning CellGro), 1% (2mM) L-glutamine
(Corning CellGro), and 1% (100M) non-essential amino acids (NEAA, Invitrogen). MCF-7/5C
cells were cultured in phenol-red free RPMI 1640 enhanced with dextran charcoal-stripped 10%
FBS to remove estradiol from the solution, as well as 1% L-glutamine and 1% NEAA.
All cell lines were maintained at 37C with 5% CO2 and 95% humidity. Experimental
medium was changed daily.
Drug Treatments
17-estradiol was purchased from Sigma Aldrich (Catalogue #E8875) and suspended in
dimethyl sulfoxide (DMSO, Sigma Life Sciences, Catalogue #D2660) to form a 25M stock
which was protected from light and maintained in -20C. This solution was diluted in growth
medium for an experimental working concentration of 5nM. 200 proof molecular grade absolute
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ethanol was purchased from Thermo Fisher Scientific (Thermo Fisher Scientific, BP2818-500)
and diluted in Phosphate Buffer Saline (PBS, Corning CellGro) to form a stock of 1, 2, or 4 M,
which was protected from light and maintained in 4C. This solution was diluted in growth
medium for an experimental working concentration of 10, 20, or 40mM respectively. A 
secretase inhibitor (GSI), MRK-003, was provided from Merck Oncology & Co. (Whitehouse
Station, NJ) and re-suspended in DMSO to create a 10mM stock solution. This solution was
diluted in growth medium for an experimental working concentration of 5M.
Table 1: Real Time RT-PCR Primers
Primer
Name
Forward Sequence
HPRT
ATGAACCAGGTTATGACCTTGAT
PGR
AGCATGTCGCCTTAGAAAGTGC
PS2
HES1
SOX2
OCT4
NANOG

GAGGCCCAGACAGAGACGTG
CGGACATTCTGGAAATGACA
CACACTGCCCCTCTCAC
GGCAACCTGGAGAATTTGTTC
AGAGAATGAAATCTAAGAGGTG
GC

Reverse Sequence
CCTGTTGACTGGTCATTACAATA
TAGGGCTTGGCTTTCATTTG
CCCTGCAGAAGTGTCTAAAATT
CA
CATTGATCTGGGTCATGCAG
TCCATGCTGTTTCTTACTCTCC
GTTACAGAACCACACTCGGAC
GTGGTAGGAAGAGTAAAGGCTG

Antibodies
Antibodies and their respective concentrations of use include: DAXX (1:1,000, 25C12,
Cell Signaling Technology); NOTCH4 (1:200, H225, Santa Cruz Biotechnologies), NICASTRIN
(1:200; Covance); -AMYLOID (1:500, H-43, Santa Cruz Biotechnologies); and -ACTIN
(1:10,000, A5411, Sigma Aldrich. -ACTIN served as a loading/endogenous control for total
protein western blots. Secondary antibodies used for band visualization include anti-rabbit and
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anti-mouse Horseradish Peroxidase (HRP) conjugated secondary antibodies purchased from Cell
Signaling (Cell Signaling Technologies).
Primers
All primers used in Reverse Transcription, quantitative real-time Polymerase Chain
Reaction (qRT-PCR) were designed using the NCBI Primer Blast and purchased from
Invitrogen. All primers were re-suspended in Nuclease-Free water to create a stock solution of
50M. Sequences for each primer used are listed in Table 1.
Experimental Methods
Western Blotting
Bicinchoninic Acid (BCA) Assay: 300L of lysis buffer (1% Triton X-100, 50mM
HEPES, 150mM sodium chloride, 5mM ethylene-diaminetetraacetic acid (EDTA), 1mM
phenylmethylsulphonyl fluoride (PMSF), 1mM sodium orthovanadate, 10mM sodium fluoride,
and 200x Protease Inhibitor Cocktail) was used to lyse cells. Cells were trypsinized and pelleted
prior to the addition of lysis buffer, then incubated on ice for 10 minutes after being suspended in
the lysis buffer. After incubation, lysates were sonicated twice for ten seconds at 20%
amplification using the Sonic Dismembrator (Model 100, Thermo-Fisher Scientific). Protein
standards of bovine serum albumin (BSA) ranging from 0 to 10g/mL were plated in duplicate at
10L per well in a 96-well plate, in addition to 10L of each lysate in duplicate. 200L of BCA
working solution (50:1 Reagent A:Reagent B, Thermo-Fisher Scientific) was added to each well.
The 96-well plate was incubated at 37C for twenty minutes, then read by a fluorescent plate
reader. Total protein concentrations were calculated via comparison of absorbance values of the
lysates to that of the standard curve generated, with an R2 value of 0.98 or greater. 20g of total-
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protein containing samples were prepared using 2X Laemmeli Buffer (Bio-Rad, Catalogue
#1610737) and -mercaptoethanol (Thermo-Fisher Scientific, Catalogue #BP-176-100), and
additional lysis buffer as needed. Samples were then boiled at 95C on a shaking hot plate for 10
minutes and stored at -20C until use.
Gel preparation: Sodium Dodecyl Sulfate (SDS) gels were prepared to separate proteins
based on their molecular weight. A clean, short glass plate was secured against a 1.5mm tall
glass spacer plate using a casting frame with the bottom of the plates completely flat and level.
The casting frame was then secured in place in a casting stand for gel preparation. Resolving and
Stacking solutions were prepared as described in Table 2 for 10% acrylamide gels. 8mL of
resolving solution was poured between the two glass plates and topped with 1mL of isopropanol
to flatten the top of the gel. Once the resolving solution solidified, the isopropanol was rinsed off
with nuclease-free water and 2mL of the stacking solution was poured onto the resolving layer.
A 1.5mm gel comb containing 10 wells was then inserted into the stacking solution, and the gels
were left to solidify. Once solidified, gels were wrapped in paper towels soaked in nuclease-free
water and stored in 4C overnight before use.
Table 2: Gel Preparation for Western Blot
10% Resolving Solution
Amount
Reagent Name
(mL)
Nuclease-Free Water
4
30% Acrylamide
3.3
1.5M Tris Buffer (pH 8.8)
2.5
10% SDS
0.1
10% Ammonium Persulfate
(APS)
0.1
TEMED
0.004

Stacking Solution
Reagent Name
Nuclease-Free Water
30% Acrylamide
1.5M Tris Buffer (pH 6.8)
10% SDS
10% Ammonium Persulfate
(APS)
TEMED

Amount
(mL)
3.4
0.83
0.63
0.05
0.05
0.005
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Western blot: Samples were boiled for 10 minutes at 95C prior to being ran for western
blot analysis. Proteins were separated by molecular weight using SDS-PAGE buffered with 8%
tris-glycine along with HiMark Prestained protein standard (Thermo-Fisher Scientific, Catalogue
#LC5699). Proteins were separated at 150V for 60 minutes in 1X Tris-glycine SDS Running
Buffer. Proteins were then transferred to a polyvinylidene fluoride membrane that had been prewetted with methanol, then water, then transfer buffer prior to use, at 100V for 60 minutes.
Following transfer, the membranes were rocked in 5% non-fat dry milk for 60 minutes at room
temperature to prevent non-specific binding of primary antibodies. After blocking, membranes
were incubated in the designated primary antibody at 4C overnight with constant agitation. The
following day, membranes were washed three times with 1X Tris-buffered Saline plus Tween-20
(TBST) for 10 minutes while rocking. After the final wash, the appropriate HRP-conjugated
secondary antibody was added to the membrane for 60 minutes at room temperature while
rocking. After the secondary antibody incubation is complete, the membranes are washed three
times with TBST for ten minutes, and then detected using enhanced chemiluminescence (ECL)
Western Blotting Substrate (Pierce), or SuperSignal West Extended Duration Substrate (ThermoFisher Scientific) if needed, in a 1:1 volume. Protein bands were visualized by exposing the
membranes to X-ray film for 30 seconds to 10 minutes, depending on however long was
necessary to visualize the bands. Reprobing was performed by washing the membrane with
stripping buffer for five minutes two times, then washed with PBS two times for five minutes,
then washed with TBST three times for ten minutes. Membranes were then blocked for thirty
minutes and incubated with primary antibody overnight. Densitometry analysis was conducted
using ImageJ software, samples were normalized to -ACTIN.
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Reverse Transcription, Real Time Polymerase Chain Reaction (PCR)
RNA extraction: 300L Ambio TRIZol Reagent was either added directly to tissue
culture plates or to cells pelleted after being trypsinized, and samples were stored in -80C until
extraction was performed. In order to extract RNA, 50L of 1-Bromo-3-chloropropane (BCP)
was added directly to the cells in the 300L TRIZol Reagent and were vortexed for 15 seconds
to mix the solution thoroughly. Samples were incubated at room temperature for 5 minutes, then
centrifuged at 14,000rpm for 15 minutes at 4C. After this, the Zymo Research Direct-zol RNA
Miniprep kit was utilized with a few modifications to the established protocol. The clear aqueous
phase was removed from each sample and placed in a clean 1.5mL Eppendorf tube, and equal
volume of 200 proof molecular grade absolute ethanol was added. The samples were vortexed
for 10 seconds to mix the solution thoroughly, then the entire sample was added to the ZymoSpin IIICG Column placed within a collection tube. Samples were centrifuged at 15,000rpm for
30 seconds. 200L of Direct-Zol Prewash Buffer was added directly to the column and samples
were spun as previously described. Then, 500L of RNA Wash Buffer was added to the column,
and samples were spun as previously described. After this, the columns were spun once again at
the same speed and time to ensure the column was completely dry of any wash buffers. Then
40L of DNAse/RNAse-free water was added to the column and left to incubate for 3 minutes at
room temperature. Samples were then spun at 15,000rpm for 30 seconds to elute the RNA, then
placed directly onto ice. The concentration of the RNA and 260/280 ratios were measured using
the NanoDrop 2000.
Reverse Transcription (RT): 0.5g of RNA from each sample was utilized to generate
25ng/L of cDNA. If necessary, RNA samples were diluted in nuclease-free water to achieve the
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desired concentration for the Reverse Transcriptase reaction. The components of each reaction
are listed in Table 3. Once the reactions are prepped, the reverse transcriptase reaction was
conducted in a thermal cycler under the following parameters: 10 minutes at 25C, 30 minutes at
48C, 5 minutes at 95C, 60 minutes at 25C, then held at 4C until use.
Table 3: Reverse Transcriptase Reaction (50µL)
Reagent Name

Amount (µL)

Final Concentration

10X RT Buffer

5

1X

25mM MgCl2

11

5.5nM

dNTPs

10

500µM/dNTP

Random Hexamers

2.5

2.5µM

RNAse Inhibitor

1

0.4U/L

RT Enzyme

1.25

1.25U/L

RNA + Nuclease Free Water

19.25

0.5µg RNA

Quantitative Real Time PCR (qRT-PCR): cDNA generated from the reverse
transcriptase reaction was used in qRT-PCR analysis, which utilized the iTaqTM SYBR® Green
Enzyme Supermix with ROX (BioRad) in a 96-well optical PCR plate. Components of the
reaction and their volumes are listed in Table 4. Once prepared, the qRT-PCR was performed
using the Applied Biosystems Step One Plus Real-Time Thermocycler as follows: initial
denature at 95C for 10 minutes, PCR cycling for 10 seconds at 95C for 40 cycles, and
annealing for 45 seconds at 60C. The average cycle threshold (Ct) was used to determine
relative gene expression for each experimental condition. Ct values are the number of cycles
necessary for the fluorescent signal to overcome the background threshold of fluorescence. C t
were normalized to the housekeeping gene Hypoxanthine-guanine phosphoribosyltransferase
(HPRT), resulting in the Ct, which was then used to determine the Ct by normalized all
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experimental samples to the control sample’s Ct. Lastly, relative fold changes were calculated
by using the 2-Ct method.
Table 4: Real Time RT-PCR Reaction (12.5µL)
Reagent Name

Amount (µL)

Final Concentration

Nuclease Free Water

4.5

-

50µM Forward Primer

0.25

12.5µM

50µM Reverse Primer

0.25

12.5µM

25ng/µL cDNA

1.25

2.5ng/µL

2X SYBR Green Master Mix

6.25

1X

Mammosphere Formation Assay
Cells were seeded at a density of 5 x 105 per dish in a 6 cm2 tissue culture dish or 1 x 106
in a 10 cm2 tissue culture dish. MCF-7 cells were grown in charcoal-stripped RPMI 1640 for 72
hours prior to being plated into experimental conditions. 24 hours after seeding, cells were
treated with DMSO or 5nM 17-estradiol in conjunction with a specified concentration of
ethanol or PBS for 72 hours. For GSI experiments, cells were also treated with 5M GSI or
equal volume DMSO during the 72-hour treatment period. After the treatment period concluded,
cells were trypsinized and harvested in charcoal stripped RPMI 1640. Cells were counted using
Trypan blue staining on the Countess Automated Cell Counter (Life Technologies). 2.5 x 10 4
cells were seeded in a 6-well non-adherent tissue culture plate coated in mammosphere forming
media [196mL DMEM F12 (Life Technologies), 3g methyl cellulose (Sigma Aldrich), 3mL B27
(Life Technologies), 3L recombinant EGF (Sigma Aldrich)]. These plates were left to incubate
at 37C and 5% CO2 for 7 days undisturbed. Following the incubation period, mammospheres
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were imaged using a Nikon Diashot TMD Fluorescence Phase Contrast Inverted microscope
(Nikon) at 4X and 10X magnification for size analysis. In order to calculate mammosphere
forming efficiency, mammospheres were extracted by adding 6mL of PBS to each well to
dissolve the mammosphere forming media. This was done twice, then the 12mL of PBSmammosphere media mixture was spun down at 1200rpm for 3 minutes to pellet the extracted
mammospheres. The supernatant was then aspirated down to 1mL, and this was transferred to a
clean 2mL Eppendorf tube. The samples were then spun down at 1200rpm for 5 minutes. The
PBS was then aspirated off, and the mammospheres were resuspended in a fresh 2mL of PBS.
50L of each sample was then placed in a flat bottom 96-well plate in addition to 200L of PBS.
Pictures were then taken of each well at 4X magnification using the same microscope to collect
the images used for size analysis. Mammosphere forming efficiency (% MFE) was determined
by counting the number of mammospheres greater than 50m with % MFE = [(number of
spheres > 50microns counted X dilution factor/number of cells plated) X 100].

CHAPTER FOUR
RESULTS
Specific Aim 1: Elucidate Potential Mechanisms By Which Alcohol Promotes Breast
Cancer Stem Cells in Naïve ER+ Breast Cancer Cells.
According to our preliminary data, when naïve ER+ breast cancer cells are treated with
increasing concentrations of ethanol, there is a significant increase in cancer stem cell survival,
as measured by %MFE regardless of the presence of 17-estradiol. These data are supported by
previous findings in HER2 overexpressing breast cancer cells (Xu et al., 2016), however
previous work has not investigated the role of 17-estradiol under these conditions. As described
previously, 17-estradiol has been shown to drive differentiation of progenitor and stem cells
within the breast, and this may be through inhibition of the Notch signaling pathway. Thus, the
goal of this aim is to test the mechanism by which alcohol promotes BCSCs, with the hypothesis
being that alcohol prevents the differentiating effects of 17-estradiol within the bulk cell
population thus promoting survival of BCSCs.
Acute Alcohol Exposure Induces Expression of CSC-Promoting Genes
We first sought to determine how exposure to ethanol directly effects the Notch signaling
pathway. Notch1 expression is known to be significantly lower in BCSCs, while Notch4
expression is significantly higher compared to the bulk cell population (Harrison et al., 2010).
Additionally, Notch1-mediated transcription is known to be negatively regulated by ER
signaling, and this inhibition is alleviated when ER is antagonized (Rizzo et al. 2008). Therefore,
30
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we deprived MCF-7 cells of estrogen by culturing them in charcoal-stripped RPMI for 72 hours.
Cells were then treated in the presence or absence of 17-estradiol in conjunction with 40mM
ethanol for an additional 72 hours, then collected and processed for qRT-PCR analysis. Changes
in the canonical Notch target, HES1, as well as the gene encoding for the Notch1 receptor were
assessed. If alcohol promotes BCSC survival through the activation of Notch signaling, then we
would expect to see an induction of HES1 transcripts when ethanol is present, additionally we
would expect to see decreased levels of NOTCH1 transcripts.

Figure 8: Expression of HES1 RNA Trends Upwards in Response to Alcohol. MCF-7 cells
were grown in charcoal-stripped phenol-red free RPMI containing 10% FBS for 72 hours. Cells
were then seeded in a 6cm2 dish and treated with either 5nM 17-estradiol or DMSO, as well as
40mM ethanol or Phosphate Buffer Saline (PBS) for 72 hours. RNA was extracted from the cells
following treatment and cDNA was synthesized. The relative expression of canonical Notch
target HES1 and NOTCH1 was measured by qRT-PCR. Results are presented as the mean + SD
of five independent experiments. All groups were compared to DMSO 0mM EtOH by Two Way
ANOVA to determine statistical significance (** = p < 0.01).
As shown in Figure 8, treatment with 5nM 17-estradiol for 72 hours significantly
inhibits HES1 transcript levels. Though not statistically significant, there is a trend towards
induction of HES1 following 72 hours of ethanol exposure under estrogen deprived conditions,
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and in the presence of 17-estradiol, though not as robust, there appears to be a slight increase in
HES1 transcript levels when cells are treated with ethanol. On the contrary, NOTCH1 transcripts
are relatively unchanged in the absence of ethanol treatment, regardless of 17-estradiol
treatment. Interestingly, there is an induction of NOTCH1 transcripts when both ethanol and
17-estradiol are present in the bulk cell population, though not statistically significant, similar
to that of HES1. Taken together, these data suggest that under estrogen deprived conditions,
alcohol may slightly activate the Notch signaling pathway, at least at the level HES1. However,
upon addition of 17-estradiol, it may be competing with ER to regulate transcription of these
genes.
To further test this hypothesis, transcript levels of pluripotent genes SOX2, OCT4, and
NANOG were measured following 72 hours of ethanol exposure in the presence or absence of
17-estradiol. As previously mentioned, 17-estradiol is known to inhibit the expression of these
genes, and alcohol may promote the BCSC population by enhancing transcription of these genes
within the bulk cell population. We see in Figure 9, that all three genes investigated are inhibited
when cells are treated with 17-estradiol in the absence of ethanol. Similar to what was observed
with HES1, there is a trend towards induction of SOX2, OCT4, and NANOG transcripts when
cells are exposed to ethanol under estrogen deprived conditions. Additionally, when 17estradiol is present, ethanol again appears to alleviate some of 17-estradiol’s inhibitory effects
on expression of these genes. Collectively, these data together suggest that alcohol tends to
protect CSCs and possibly reverse the differentiating effects of 17-estradiol.
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Figure 9: Alcohol Treatment Trends Toward Inducing Expression of Pluripotent Genes.
MCF-7 cells were treated and processed as described previously for qRT-PCR analysis of the
pluripotent genes SOX2, OCT4, and NANOG following 72 hours of treatment with 40mM
ethanol in the presence or absence of 5nM 17-estradiol. Results are presented as the mean + SD
of five independent experiments. All groups were compared to DMSO 0mM EtOH by Two Way
ANOVA to determine statistical significance (** = p < 0.01).
Alcohol Attenuates Transcriptional Regulation of ER Targets by 17-estradiol
Our previous findings suggest that alcohol may interfere with the ability of 17-estradiol
to induce transcriptional changes of its target genes. We saw that when MCF-7 cells were treated
with alcohol and 17-estradiol in combination for 72 hours, the repressive effects of ER on
pluripotent genes and HES1 were partly alleviated, though not significantly. It is possible that
alcohol may be directly inhibiting ER, so to test this, we deprived MCF-7 cells of 17-estradiol
for 72 hours in charcoal-stripped RPMI. We then treated these cells for 72 hours with 40mM
ethanol and added 5nM 17-estradiol for either 0, 3, or 24 hours, as ER is known to have
immediate effects on transcription, as quickly as 30 minutes following 17-estradiol exposure
(Stossi et al., 2004, Jagannathan & Robinson-Rechavi, 2011). Analysis of canonical ER early
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target genes PS2, or Trefoil Factor 1, and PGR, the Progesterone Receptor, was conducted by
qRT-PCR as previously described. If ethanol promotes CSCs through inhibition of immediate
ER transcriptional regulation, then we would expect that PS2 and PGR transcript levels would be
lower in ethanol treated cells compared to untreated controls.
As shown in Figure 10, treatment with 5nM 17-estradiol induces expression of both PS2
and PGR transcripts in as little as 3 hours, and further increased by 24 hours. Interestingly,
40mM ethanol also induces expression of these transcripts in the absence of 17-estradiol.
Further, addition of 17-estradiol to alcohol-treated cells did not increase transcripts compared to
the absence of 17-estradiol. Taken together these data suggest that alcohol alone is sufficient to
activate classical ER signaling and may compete for regulation of ER target genes when 17estradiol is present in ER+ breast cancer cells.

Figure 10: Alcohol Alone Induced Expression of Classical ER Target Genes. MCF-7 cells
were grown in charcoal-stripped phenol-red free RPMI containing 10% FBS for 72 hours. Cells
were then seeded in a 6cm2 dish and treated with either 40mM ethanol or PBS for 72 hours.
Additionally, cells were treated with 5nM 17-estradiol for either 0, 3, or 24 hours, then
collected and processed for qRT-PCR analysis of the classical early ER target genes PS2 and
PGR. Results are presented as the mean + SD of three independent experiments. All groups were
compared to 0 hours 5nM estradiol + 0mM EtOH by Two-Way ANOVA to determine statistical
significance. (** = p < 0.01, *** = p < 0.001, **** = p < 0.0001).

35
Alcohol Promotes Expression of Notch4 in a Dose-Dependent Manner
Notch signaling is activated when a ligand-expressing cell comes into contact with one of
the four Notch receptors on the surface of a neighboring cell. Upon ligand activation, the
receptor then undergoes cleavage by ADAM10 or ADAM17, which then exposes the two
cleavage sites for the -secretase complex S3 and S4 (Schweisguth, 2004). As mentioned
previously, Notch4 is known to be a critical promoter of ER+ BCSC survival, thus we decided to
assess changes in Notch4 expression within the bulk cell population following exposure to
ethanol. MCF-7 cells were deprived of 17-estradiol for 72 hours, then treated with increasing
concentrations of ethanol in the presence or absence of 5nM 17-estradiol for an additional 72
hours. They were then collected and processed for protein expression analysis via western blot. If
alcohol promotes BCSC survival through Notch4 activation, then we would expect to see
increased protein expression of the Notch4 receptor.
Figure 11 demonstrates that when cells are grown in the presence of 17-estradiol,
Notch4 expression is downregulated compared to cells grown under estrogen deprived
conditions, as indicated by the 70kDa band. Interestingly, alcohol appears to upregulate Notch4
expression regardless of whether 17-estradiol is present or not. If the multiple bands located
between 55 and 40kDa are specific to Notch4, then this would also indicate an increase in the
cleaved receptor, and indicate activation of the Notch4 signaling pathway, which would further
suggest that alcohol promotes the expression and activation of Notch4 in naïve ER+ cells.
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Figure 11: Alcohol Dose-Dependently Enhances Notch4 Protein Expression. MCF-7 cells
were grown in charcoal-stripped phenol-red free RPMI for 72 hours, then treated with increasing
concentrations of ethanol in the presence or absence of 5nM 17-estradiol for an additional 72
hours. Total protein was isolated from the cells and lysates quantified for western blot analysis of
Notch4 using -Actin as the loading control.
We next sought to determine potential mechanisms by which alcohol enhances Notch4 in
these cells. Peiffer and colleagues established that Notch4 is negatively regulated by the Death
Domain Associated Protein 6 (DAXX), which is stabilized by 17-estradiol and also known to
inhibit BCSCs (Peiffer et al., 2019). Thus, if alcohol promotes BCSC survival through the
activation of Notch4, then this may be through downregulation of its repressor, DAXX. As our
previous findings show, alcohol appears to disrupt regulation of ER targets at the level of
transcription, however it is unknown how alcohol affects ER activity at the protein level. Using
the same membrane for Notch4 analysis, the blot was stripped and re-probed using a primary
antibody against DAXX.
As shown in Figure 12, DAXX protein expression is depleted under estrogen deprived
conditions and stabilized in the presence of 17-estradiol. Interestingly, alcohol appears to

37
enhance DAXX expression when 17-estradiol is present in a dose-dependent manner yet has
little effect on its expression under estrogen deprived conditions. Collectively, these data suggest
that alcohol enhances Notch4 expression in a dose-dependent manner, and this effect may be
independent of ER-mediated regulation of the Notch4 receptor by DAXX.

Figure 12: Alcohol Dose-Dependently Enhances DAXX Protein Expression in the Presence
of 17-estradiol. Total protein was isolated from MCF-7 cells as previously described for
western blot analysis of DAXX using -Actin as the loading control.
The Effect of -Secretase Inhibition in Bulk and/or BCSCs on BCSC Survival
It is known that inhibition of Notch signaling within the BCSC population alone is
sufficient to inhibit their survival, as shown by a decrease in MFE (Grudzein et al., 2010).
However, the effect of pre-treating bulk cell populations alone with a -secretase inhibitor (GSI)
on BCSC survival, and whether this is affected by exposure to alcohol, has yet to be elucidated.
To test this, MCF-7 cells were deprived of 17-estradiol for 72 hours, then treated with 20mM
ethanol in the presence or absence of 17-estradiol for 72 hours. During the ethanol/estradiol
treatments, cells were additionally treated with 5M GSI (MRK-003) or a DMSO vehicle. After
completing their treatments, cells were seeded in mammosphere forming medium in the presence
or absence of the GSI at a density of 2.5 x 104 and incubated for 7 days at 37C (Figure 13).
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Figure 13: Experimental Design of -Secretase Complex Inhibition in Bulk Cells and/or
BCSCs. MCF-7 cells were treated as previously described with DMSO or 5nM 17- estradiol
(E2) in combination of GSI alone, 20mM ethanol alone, or a combination of the two. 2.5 x 104
cells were seeding in mammosphere media and treated with 5M GSI or DMSO for 24 hours,
then incubated for an additional 6 days, following which %MFE was determined.
Alcohol May Promote the Interaction of the -Secretase Complex with Notch4
We confirmed inhibition of the -secretase complex by assessing the protein expression
of the classical -secretase substrate, -amyloid precursor protein (APP), as well as Nicastrin, a
component of the -secretase complex that serves as a gatekeeper for substrate interaction with
Presenilin’s active site (Bolduc et al., 2015, Wolfe, 2020). Our findings demonstrate that
treatment with the GSI results in decreased APP expression and cleavage, as well as decreased
expression of Nicastrin. This suggests that these cells are sensitive to GSI, and the effect of the
GSI on classical -secretase complex substrates is not altered by co-treatment with ethanol.
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Figure 14: Confirmation of -Secretase Complex Inhibition by Target Protein Expression
Analysis. MCF-7 cells were grown in charcoal-stripped phenol-red free RPMI for 72 hours.
Then they were treated with 5nM 17-estradiol or DMSO alone or in combination with 5M
GSI (MRK-003) and/or 20mM ethanol. Total protein was isolated from the cells and lysates
quantified for western blot analysis of -Amyloid Precursor Protein and Nicastrin using -Actin
as the loading control.
Knowing that GSIs act as pan-Notch inhibitors and with a lack of data to suggest whether
the -secretase complex shows specificity towards one Notch receptor over another (OlsauskasKuprys et al., 2013), we next investigated changes in Notch4 protein expression under these
conditions. In Figure 15, we see an accumulation of Notch4 protein, specifically at 70kDa, when
cells are treated with GSI, in the presence and absence of 17-estradiol (lanes 1-4). We also see
that when cells are treated with 20mM ethanol, Notch4 expression is enhanced compared to
untreated controls (lanes 1, 3, 5, & 7), as shown previously. Interestingly, when cells are treated
with the GSI in the presence of 20mM ethanol, there is a significant accumulation of Notch4
protein at the 70kDa molecular weight compared to cells grown in the absence of ethanol (lanes
2, 4, 6, & 8). Because alcohol had no effect on the classical -Secretase complex substrate APP,
yet we see a marked changed in Notch4 expression following GSI treatments when alcohol is
present, these data may suggest that alcohol promotes -secretase-mediated cleavage of Notch4
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through increased expression of Notch4 and thus increased availability of this substrate
compared to others.

Figure 15: Accumulation of Notch4 Following -Secretase Inhibition is Enhanced by
Exposure to Alcohol. Total protein was isolated from MCF-7 cells as previously described, and
western blot analysis of Notch4 was performed using -Actin as the loading control.
BCSCs are Resistant to GSI Treatment in Bulk Cells Prior to Selection
As our findings suggest, MCF-7 cells are sensitive to GSI treatments in the bulk cell
population, as shown by the decreased protein expression of the classical -secretase substrate
APP. However, how inhibition of -secretase complex in the bulk cells affects BCSC survival
has yet to be elucidated. As described previously (Figure 13), after 72-hour co-treatments of GSI
and 20mM ethanol in the presence or absence of 17-estradiol, MCF-7 cells were plated in
mammosphere forming medium and treated with 5M GSI or equal volumes of DMSO vehicle
for 24 hours. If Notch activation in the bulk cells is required for BCSC survival, then we would
expect that pre-treatment with the GSI in the bulk cells alone would inhibit mammosphere
formation. Additionally, if alcohol-mediated promotion of BCSC survival is dependent on Notch
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activation in the bulk cell population, then we would expect to see a decrease in mammosphere
forming efficiency (MFE) following pre-treatment with the GSI in bulk cell populations. In
contrast, if Notch activation is not required for alcohol-mediated promotion of BCSCs, then we
would expect to see no change in MFE in BCSCs that are treated with the GSI for 24 hours,
compared to untreated controls.
As shown in Figure 16, cells grown in the presence of 17-estradiol have a lower MFE
compared to cells grown under estrogen deprived conditions (red bars 1 and 2). Additionally,
treatment with 20mM ethanol enhanced the MFE of cells grown in the presence of 17-estradiol,
however we failed to see this in estrogen deprived cells unlike our previous experiments (red
bars 3 and 4). When bulk cells are pre-treated with the GSI alone, we see no significant change
in MFE in the presence or absence of 17-estradiol (pink bars 1 and 2). Interestingly, pretreatment with the GSI in combination with ethanol does not affect MFE when 17-estradiol is
present (pink bar 3), however co-treatment with GSI and ethanol under estrogen deprived
conditions show a downward trend in MFE, though not statistically significant (pink bar 4).
Overall, BCSCs appear to be resistant to -secretase inhibition in bulk cell populations prior to
selection.
Alcohol Promotes Resistance in GSI-Treated BCSCs
We further sought to determine if GSI pre-treatment in combination with direct treatment
of the BCSCs would affect alcohol’s ability to promote BCSC survival. We hypothesized that if
alcohol promotes BCSC survival through the activation of Notch signaling, then we would see a
decrease in MFE in BCSCs pre-treated with ethanol and plated in GSI containing media. If
Notch signaling is not required for alcohol-mediated BCSC survival, then we would anticipate
seeing little change in MFE in GSI-treated BCSCs compared to untreated controls.
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As expected, GSI treatment in BCSCs alone results in complete inhibition of
mammosphere formation in the presence or absence of 17-estradiol (Figure 16, dark green bars
1 & 2). The addition of 20mM ethanol prior to GSI treatment in the BCSCs does not appear to
protect against this effect (dark green bars 3 & 4). Of note, pre-treatment of the bulk cell
population with 5M GSI prior to GSI treatment in the BCSC population shows a positive trend
in MFE in cells grown in the absence of ethanol (light green bars 1 & 2). When co-treated with
20mM ethanol, this effect is unchanged for cells grown in the presence of 17-estradiol (light
green bar 3), however co-treatment with the GSI and 20mM ethanol in bulk cells deprived of
estrogen prior to GSI treatment in the BCSC population show no resistance to the GSI (light
green bar 4).
Collectively, these data suggest that alcohol promotes the expression of Notch4 which
may increase its availability to interact with the -secretase complex. This interaction appears to
be necessary for alcohol-mediated promotion of BCSC survival when 17-estradiol is absent.
Interestingly, pre-treatment of bulk cell populations with GSI prior to 24-hour treatment of
BCSCs with GSI results in a -secretase independent population. This is most pronounced when
cells are grown in the absence of estrogen and ethanol or in the presence of both. However, when
cells are grown in the absence of estrogen, but the presence of ethanol, this resistance is not seen.
These data suggest that -secretase complex activity is a necessary component of alcoholmediated BCSC survival in the absence of 17-estradiol, but not required for alcohol-mediated
BCSC survival in the presence of 17-estradiol.
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Figure 16: GSI Treatment in Bulk Cell Populations Results in Resistant BCSC Populations.
Cells were grown under conditions previously described in the presence or absence of 17estradiol, as well as 20mM ethanol and/or 5M GSI, then plated in mammosphere forming
medium and treated for 24 hours with 5M GSI or a DMSO vehicle. Results are presented as the
mean + SD of three independent experiments. Two-Way ANOVA with Tukey’s multiple
comparisons analysis was used to determine statistical significance. (* = p < 0.05).
Specific Aim 2: Determine the Effect of Alcohol on Long-Term Estrogen Deprived ER+
Breast Cancer Stem Cells
As mentioned previously, there is a critical need for investigation into the effects of
alcohol on a clinically relevant model of endocrine therapy. The MCF-7/5C cell line was
originally derived from the naïve ER+ MCF-7 cell line, but this clone has required resistance to
estrogen deprivation and no longer depends on 17-estradiol for its proliferation. The clinical
data currently available suggests that post-menopausal women or women who are currently or
successfully completed endocrine therapy are at most risk in terms to the negative impacts of
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alcohol consumption on breast cancer recurrence. Thus, the goal of this aim was to verify
whether exposure to ethanol in a long-term estrogen deprived (LTED) cell line would alter the
BCSC population as we see in the naïve parental cells. Specifically, we examined how the
changes seen in the parental cell line differed in the LTED cells in response to ethanol treatment
in the presence or absence of 17-estradiol. We hypothesized that if alcohol poses a greater risk
under estrogen deprived conditions, then we would expect these cells to be more sensitive to
alcohol mediated BCSC survival, potentially through the activation of Notch signaling.
We treated MCF-7/5C cells with increasing concentrations of ethanol in the presence or
absence of 17-estradiol for 72 hours, then seeded 2.5 x 104 cells in mammosphere forming
medium, as previously described. Mammosphere forming efficiency was then calculated after
the 7-day incubation period. As shown in Figure 17, 17-estradiol inhibits BCSC survival in
these cells compared to estrogen-deprived conditions. Alcohol does not have any apparent effect
on BCSC survival under estrogen-deprived conditions, however there is a positive trend in
%MFE when cells are treated with increasing concentrations of ethanol in the presence of 17estradiol, though not statistically significant.
We next investigated whether this trend seen in the 17-estradiol treated cells could be
explained by changes in Notch signaling. As we saw in the naïve ER+ cells, increasing
concentrations of ethanol increased Notch4 expression and cleavage, and Notch activity is
known to be elevated in LTED cells (Faronato et al., 2015). We collected cells for protein
analysis as previously described and assessed changes in both Notch4 and DAXX protein
expression following 72 hours of treatment with increasing concentrations of ethanol. If alcohol
promotes BCSC in LTED cells in the presence of 17-estradiol, then we would expect to see
increases in Notch4 expression and cleavage in ethanol treated cells compared to controls.
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Additionally, we would expect to see decreased DAXX expression under conditions when
Notch4 expression is high.
Figure 18 shows that treatment with ethanol upregulates expression of Notch4 in LTED
ER+ cells, though there appear to be no significant changes in the cleavage of this receptor. In
contrast to this, alcohol dose-dependently upregulates DAXX expression in both the presence
and absence of 17-estradiol. Collectively, these data suggest that alcohol may promote BCSC
survival in the presence of 17-estradiol independently of Notch4, but possibly through changes
in 17-estradiol regulation at the protein level.
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Figure 17: Alcohol Exposure Trends Towards Enhanced BCSCs Survival in E 2 treated
LTED ER+ Cells. MCF-7/5C cells were grown in charcoal-stripped phenol-red free RPMI and
treated with either 5nM 17-estradiol or DMSO, as well as increasing concentrations of ethanol
or PBS for 72 hours. 2.5 x 104 cells were seeded in mammosphere media and incubated for 7
days, following which %MFE was calculated. Results are presented as the mean + SD of three
independent experiments. Two-Way ANOVA with Tukey’s multiple comparisons analysis was
used to determine statistical significance
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Figure 18: Alcohol Enhances Notch4 and DAXX protein expression in LTED ER+ cells.
MCF-7/5C cells were grown in charcoal-stripped phenol-red free RPMI and treated with 5nM
17-estradiol or DMSO alone or in combination with increasing amounts of ethanol. Total
protein was isolated from the cells and lysates quantified for western blot analysis of Notch4 and
DAXX using -Actin as the loading control.

CHAPTER FIVE
DISCUSSION
Notch signaling is a known contributor to BCSC survival and has been implicated in
resistance to endocrine therapy as well as tumor recurrence (Rizzo et al., 2008, Peiffer et al.,
2019), thus providing a rationale to investigate changes in this pathway in response to alcohol
exposure. ER is a known inhibitor of Notch signaling shown in Figure 19 (BeLow & Osipo,
2020), and demonstrated in our findings by the significant decrease in HES1 transcripts in 17estradiol treated cells compared to DMSO controls. However, the effect of alcohol on Notch
activity and on 17-estradiol’s ability to regulate this pathway had yet to be elucidated. Our
findings demonstrate there is a trend towards Notch activation following alcohol exposure in the
presence or absence of 17-estradiol. This pattern is also reflected in the pluripotent genes SOX2,
OCT4, and NANOG, suggesting that alcohol helps to maintain a stem-like state within the bulk
cell population through activation of Notch signaling, which correlates with increased expression
of pluripotent genes. Additionally, these data suggest that alcohol interferes with the ability of
17-estradiol to negatively regulate its downstream targets at least in part. Due to the level of
variance seen in the induction of these transcripts, it would be advantageous to directly assess
changes in expression of these transcription factors using a fluorescent reporter to determine
changes in their promoter activity. Alternatively, we can assess if the induction that is seen is due
to Notch activation by targeting the Notch receptors via siRNA and determine if this positive
trend towards induction is still seen.
47
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To determine if there is a direct effect of alcohol on ER activity, we investigated changes
in classic ER target genes PS2 and PGR in response to 72 hours of treatment with 40mM ethanol
prior to 0-, 3-, or 24-hour treatments of 5nM 17-estradiol. This allows us to determine whether
alcohol prevents the activation of ER target genes in response to 17-estradiol. As expected, both
PS2 and PGR transcripts were significantly induced with 3 hours of17-estradiol, and this was
further enhanced at 24 hours of 17-estradiol exposure. Interestingly, treatment with 40mM
ethanol alone for 72 hours resulted in a significant increase in PS2 and PGR transcripts in the
absence of 17-estradiol. However, when 17-estradiol is introduced to ethanol-treated cells, its
ability to further enhance these transcript levels appears to be attenuated, though not statistically
significant. Studies that have investigated the effect of alcohol on ER signaling use significantly
higher doses of ethanol (80-100mM) which may not be physiologically relevant in the breast
(Fan et al., 2000), and several studies have reported increased total protein expression of ER in
response to increasing concentrations of ethanol (Fan et al., 2000, Etique et al., 2004).
In order to determine if changes in these target genes are in fact due to ER, a
knockdown approach using siRNA targeted against ESR1 would be necessary. If alcoholmediated induction of PS2 and PGR is due to activation of ER independent of 17-estradiol,
then we would anticipate that knockdown of the ESR1 gene would prevent the induction of these
transcripts by alcohol alone, similar to that of estrogen deprived non-alcohol treated controls. It
would also be beneficial to assess changes in the phosphorylation of ER following treatment
with ethanol, as it is known that ER can be activated independent of estradiol through
phosphorylation by MAP kinases (Yue et al., 2002). Interestingly, a study conducted by
Weitsman and colleagues found that increases in reactive oxygen species (ROS) in HER2-
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overexpressing MCF-7 cells resulted in activating phosphorylations of ER on serine 118 and
167 (Weitsman et al., 2009), which may suggest an alternative mechanism by which alcohol
promotes an estrogenic effect within these cells in the absence of 17-estradiol.
Knowing that Notch signaling is regulated by 17-estradiol, more specifically ERmediated stabilization of DAXX at the protein level directly correlates with decreased expression
of Notch4 protein, as shown in Figure 19 (Peiffer et al., 2019), we sought to determine whether
alcohol disrupted 17-estradiol-mediated regulation of Notch. To do so, we examined changes in
Notch4 expression, as well as the protein expression of DAXX, in response to increasing
concentrations of ethanol in the presence or absence of 17-estradiol. When 17-estradiol is
present, Notch4 expression is inhibited compared to estrogen deprived conditions, whereas
DAXX expression is enhanced. Interestingly, we see that Notch4 expression is upregulated by
increasing concentrations of ethanol, regardless of whether or not 17-estradiol is present. In
addition to this, alcohol also increases the protein expression of DAXX, but only in the presence
of 17-estradiol. These finding support the hypothesis that alcohol helps to promote BCSC
survival through upregulation of Notch4 in the bulk cell population. However, these data suggest
that this is independent of alcohol’s effects on estrogen signaling. It is possible that alcohol
disrupts 17-estradiol – mediated transcriptional regulation by the prevention of nuclear
translocation of the ER, or its protein targets such as DAXX (Figure 20).
If alcohol prevents the translocation of DAXX to the nucleus, then it will no longer be
able to bind to the NOTCH4 promoter to inhibit its transcription, thus resulting in enhanced
Notch4 expression when alcohol is present. Alternatively, alcohol may compete with estradiol
for the ER itself, and thus we see diminished ER transcriptional activity due to competition of
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the ligands for the receptor (Figure 20). To directly test whether alcohol disrupts translocation of
either ER or DAXX, we could use immunofluorescence to determine changes in the cellular
localization of either protein following exposure to ethanol. Similarly, we could perform nuclear
fractionation to determine if the changes seen in the protein expression of DAXX, or ER, are
reflective of increased DAXX in the cytosol versus the nucleus. Thus, if alcohol prevents the
translocation of ER and/or DAXX to the nucleus and thus preventing their ability to regulate
transcriptional activity, then we would expect to see an increase in the protein levels of cytosolic
DAXX or ER, or increased fluorescence within the cytosol, compared to that of the nucleus
following exposure to ethanol.

Figure 19: Regulation of Notch Signaling by 17-estradiol -mediated Activation of the
Estrogen Receptor. Upon activation by 17-estradiol, ER is known to stabilized DAXX protein
expression. DAXX translocates to the nucleus upon 17-estradiol mediated activation of ER,
where it acts as a transcriptional repressor of pluripotent genes and Notch4, thus resulting in
inhibition of BCSC survival. Upon estrogen deprivation, DAXX repression of Notch4
transcription is alleviated, and BCSC survival is enhanced.
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Figure 20: Alcohol Regulation of 17-estradiol Mediated ER Activity. In the presence of
17-estradiol, alcohol partially disrupts the ability of ER to regulate transcription of its
downstream targets, including classical targets such as PS2 and PGR. This may be explained by
competition between alcohol and estradiol for occupation of the ER. Additionally, although
DAXX protein expression is enhanced in the presence of 17-estradiol and alcohol, its ability to
repress transcription of its targets such as SOX2 and HES1, and presumably NOTCH4, is
diminished thus resulting in increased expression and activity of the Notch4 receptor in the
presence of alcohol.
We can assess whether Notch activation is necessary for alcohol-mediated BCSC
survival through the use of a pan Notch inhibitor (GSI), MRK-003, which inhibits the catalytic
activity of the -secretase complex. We first sought to determine if alcohol was increasing
overall Notch activity in the bulk cell population to enhance the BCSC population, and thus
MCF-7 cells were pre-treated with the GSI for 72 hours prior to plating into mammosphere
media. Our findings show that BCSCs are resistant to Notch inhibition in the bulk cell population
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alone in the absence of ethanol. Additionally, when alcohol is added to GSI, in the presence or
absence of 5nM 17-estradiol in bulk cell populations, this resistance is maintained.
We further explored this by adding GSI treatment directly to the mammosphere media for
24 hours to determine if Notch activation within the BCSC population was necessary for alcohol
mediated BCSC survival. GSI treatment of BCSC with no prior pre-treatment of the bulk cell
population with GSI or alcohol completely inhibits mammosphere formation, which is supported
by previous findings (Harrison et al., 2010). Interestingly, when the bulk cell population is pretreated with the GSI followed by GSI treatment of the BCSC population, a GSI-resistant
population persists within the BCSCs regardless of17-estradiol. The addition of 20mM ethanol
further enhances this resistant population when 17-estradiol is present, however when ethanol is
given under estrogen deprived conditions and the -secretase complex is inhibited in both the
bulk and BCSC populations, there is virtually no mammosphere formation observed.
Collectively, these data suggest that alcohol promotes ER+ BCSC survival by
upregulation of the Notch4 receptor in bulk cell populations, making it more available for
activation by its ligands as well as increased likelihood of interaction with the -secretase
complex. This effect appears to be necessary for alcohol-mediated promotion of BCSC survival
when 17-estradiol is absent. However, in the presence of 17-estradiol, alcohol-mediated
BCSC survival appears to be independent of -secretase complex activity. We can further assess
whether alcohol promotes the BCSC population within the bulk cells by performing flow
cytometry to sort out cell populations based on stem cell markers. More specifically, we could
sort based on CD44+/CD24-/low expression, ALDH+ vs. ALDH- populations, or we can assess
changes in the surface expression of the various Notch receptors and/or their ligands. This would
further clarify if alcohol promotes an increase in BCSCs within the bulk cell population as well
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as directly assess changes in the Notch signaling pathway based on surface expression of each
receptors and their ligands.
It is plausible that alcohol may be acting independently of Notch signaling to promote
BCSCs. Studies have shown that alcohol can induce activation of Wnt signaling to promote
alcohol-associated hepatocellular carcinoma (Hennig et al., 2006), and Wnt/-catenin signaling
has been shown to promote BCSCs (Tang et al., 2019, Cai et al., 2013, and Jang et al., 2015).
Alternatively, BCSCs can be promoted through activation of NF-B (Yamamoto et al., 2013,
Zhou et al., 2008), Hippo YAP/TAZ pathway (Cordenonsi et al., 2011), and others (Zhou et al.,
2007, Bai et al., 2020). Thus, utilizing unbiased approaches such as RNA Sequencing may prove
to be essential in narrowing down the pathways necessary for alcohol-mediated BCSC survival
independent of the -secretase complex.
In addition to our work in naïve ER+ cells, we investigated the effects of alcohol on
BCSCs using a long-term estrogen deprived ER+ cell line MCF-7/5C. There is a deficit in the
knowledge of how estrogen deprivation changes the effects of alcohol on breast cancer, yet the
clinical data suggests that post-menopausal women or women undergoing endocrine therapy are
most at risk for the cancer-promoting effects of alcohol consumption (Kwan et al., 2013,
Simapivapan et al., 2016). Although our data did not show a statistically significant change in
overall BCSC survival following treatment with ethanol, the trends in both Notch4 and DAXX
protein expression were similar. Due to time constraints, we were unable to pursue the
hypothesis that alcohol disrupts transcriptional regulation mediated by 17-estradiol in these
cells, however our current data supports that this may also be true for LTED ER+ cells. This is of
particular importance in terms of pre-menopausal women who have already undergone endocrine
therapy and then choose to consume alcohol later in life.
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In summary, this project has demonstrated that alcohol exposure in ER+ breast cancer
poses a significant risk to breast cancer patients through the promotion of BCSCs. Potentially,
alcohol may promote BCSC survival through disruption of estrogen- mediated transcriptional
regulation, resulting in increased Notch activity which has been correlated with cellular
transformation, endocrine therapy resistance, and tumor recurrence. Future studies should
investigate whether exposure to alcohol disrupts the translocation of ER and/or DAXX to the
nucleus, and how this correlates with the changed expression in their target genes as shown in
this study. Additionally, more work is necessary to determine whether alcohol exposure
promotes enhanced tumorigenicity of BCSCs or increases tumor recurrence using an in vivo
model. Furthermore, future experiments should be aimed towards reducing the level of variance
seen within these experiments by identifying specific cell populations through sorting via flow
cytometry, or through genetic knockout of prospective alcohol-regulated targets such as Notch4
or ER. Together, these data will provide further insight into the molecular mechanisms by
which alcohol promotes ER+ breast cancer development and recurrence.
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